English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/48232
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorHerrera, Elena-
dc.contributor.authorTenckhoff, Solveig-
dc.contributor.authorGómara Elena, María José-
dc.contributor.authorGalatola, Ramona-
dc.contributor.authorBleda, María J.-
dc.contributor.authorGil, Cristina-
dc.contributor.authorErcilla, Guadalupe-
dc.contributor.authorGatell, José M.-
dc.contributor.authorTillmann, Hans L.-
dc.contributor.authorHaro Villar, Isabel-
dc.identifier.citationJournal of Medicinal Chemistryes_ES
dc.description.abstractThe use of synthetic peptides as HIV-1 inhibitors has been subject to research over recent years. Although the initial therapeutic attempts focused on HIV-coded enzymes, structural HIV proteins and, more specifically, the mechanisms that the virus uses to infect and replicate are now also considered therapeutic targets. The interest for viral fusion and entry inhibitors is growing significantly, given that they are applicable in combined therapies or when resistance to other antiretroviral drugs is seen and that they act before the virus enters the cell. The 124 synthetic sequences of the GBV-C E2 envelope protein have been obtained by SPPS. The interaction of certain GBV-C peptide sequences with the HIV-1 fusion peptide has been proven through the use of biophysical techniques. We also show how GBV-C E2 domains notably decrease cellular membrane fusion and interfere with the HIV-1 infectivity in a dose-dependent manner, highlighting their potential utility in future anti-HIV-1 therapies.es_ES
dc.description.sponsorshipThis work was funded by Grants CTQ2006-15396-CO2-01/BQU and CTQ2009-13969-CO2-01/BQU from the Ministerio de Ciencia e Innovación, Spain. E.H. is the recipient of predoctoral grant (JAE program, CSIC, Spain). We also acknowledge Dr. Rafel Prohens (Scientific Parc of Barcelona), Dr. Ricardo Gutierrez (Pompeu Fabra University), and Dr. Julià Blanco (Fundació IRSI Caixa) for the discussion of ITC, SPR, and inhibition of cell−cell binding studies, respectively. The following reagent was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB C34 peptide from DAIDS, NIAID.es_ES
dc.publisherAmerican Chemical Societyes_ES
dc.titleEffect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infectiones_ES
dc.description.peerreviewedPeer reviewedes_ES
Appears in Collections:(IQAC) Artículos
Files in This Item:
There are no files associated with this item.
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.